hsCRP assay in post-myocardial infarction patients
Research type
Research Study
Full title
An Exploratory Clinical Study to Assess a Novel hsCRP Assay in Post-Myocardial Infarction Patients.
IRAS ID
207083
Contact name
Arun Baksi
Contact email
Sponsor organisation
Novartis Pharma AG (Near Patient Testing Team)
Duration of Study in the UK
0 years, 2 months, 13 days
Research summary
A point-of-care test (POCT) that measures the levels of high sensitivity C-reactive protein (hsCRP)in blood is being developed to establish the chances of getting future heart disease (eg. heart attack) in patients who have previously experienced heart disease.
C-reactive protein (CRP) is present in blood in small amounts and elevated in situations where there is injury, inflammation (damage to cells) and heart/blood vessel disease (eg. heart attack, stroke). CRP is not easily measured in blood and a high sensitivity test is needed.
The study is sponsored by Novartis and will enrol up to 180 patients who have had a myocardial infarction. Eligible patients will have up to 4 fingerprick blood samples collected plus up to approximately 50ml of venous blood.REC name
South Central - Berkshire B Research Ethics Committee
REC reference
17/SC/0027
Date of REC Opinion
31 Jan 2017
REC opinion
Favourable Opinion